GCD was originally extracted from the human placenta and processed through a series of steps to obtain N-glycans containing terminal mannose residues, thereby targeting the mannose receptor (MR) on macrophages to treat GD. However, the source of the placenta is limited, so there is an urgent need to develop GCD from other sources. Based on this, Creative Biolabs provides professional bio-better glucocerebrosidase glycoengineering services.
